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1. Introduction 
According to the American Cancer Society (American Cancer Society, 2011), there were 
approximately 21,880 new cases of ovarian cancer in the US in 2010, representing ~3% of all 
cases of newly diagnosed cancer. It is estimated that 13,850 women died from the disease in 
the same year, thus ranking ovarian cancer as the fifth leading cause of cancer death in the 
US, only behind lung, breast, colorectal, and pancreatic. These five cancers account for over 
60% of cancer deaths in the US.  The high mortality rate associated with ovarian cancer is 
attributable largely to its diagnosis at later stages of progression (Choi et al., 2007) when 
treatment options are limited and often ineffectual. In the early stages of the disease, most 
patients are asymptomatic or exhibit rather non-specific symptoms or discomfort.  
Epidemiological evidence has established that risk factors for ovarian cancer include a 
family history of ovarian or breast cancer, often arising from mutations in the BRCA1 or the 
BRCA2 gene, occurrence of breast cancer, again often due to the same mutations, high body 
weight, and the use of just estrogen without added progesterone for postmenopausal 
hormone therapy. Some protection appears to arise from oral contraceptives, pregnancy, 
tubal ligation, and perhaps hysterectomy (American Cancer Society, 2011). 
The etiology of ovarian cancer is overall poorly understood. There is, however, a prevailing 
theory that the pituitary gonadotropins, luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH), may be contributory to the development or progression of the disease. The 
gonadotropins are heterodimeric glycoprotein hormones characterized by a common ǂ- 
subunit and a hormone specific ǃ-subunit. Both LH and FSH have been shown to have 
numerous effects on cultured ovarian carcinoma cells (Choi et al., 2007; Leung & Choi, 2007; 
Mandai et al., 2007; Lau et al., 2010). Moreover, the G protein-coupled receptors for LH 
(LHR) and FSH (FSHR) are expressed in the epithelial cells of the ovary (Choi et al., 2007). In 
the postmenopausal years, serum concentrations of LH and FSH are high due to the lack of 
negative feedback to the hypothalamus and pituitary concomitant with cessation of ovarian 
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function. The structural and functional aspects of gonadotropins and their receptors have 
been recently reviewed (Ascoli & Puett, 2009).  
In contrast to the above suggestion that gonadotropins are involved in the initiation or 
progression of the disease, there are clinical reports showing very little evidence that the use 
of gonadotropins to treat infertility increases the risk of ovarian cancer (Mosgaard et al., 
1997; Sanner et al., 2009). Considering the available data, including gonadotropin ablation 
with gonadotropin-releasing hormone (GnRH) analogs, the conclusion was reached that if 
gonadotropins are involved in ovarian cancer, their role is probably more important in 
tumorigenesis and early growth, not in later stages (Huhtaniemi, 2010). 
In this controversial area surrounding gonadotropins and ovarian cancer, there are a 
number of mixed, often conflicting, reports on established ovarian cancer cell lines 
regarding the actions of gonadotropins on cell proliferation, invasion, and migration (Choi 
et al., 2007). Consequently, a thorough examination of LH action on gene expression may 
aid in determining if LH contributes to any of the essential components of cancer such as 
self-sufficiency in growth signals, evasion of apoptosis, bypassing growth inhibitors, 
sustained angiogenesis, activation of metastasis and invasion, indefinite replication, evasion 
of immune destruction, and altered metabolism (Hanahan & Weinberg, 2011). 
There is also considerable interest in developing diagnostic biomarkers for ovarian and 
other cancers at early stages. We have explored a novel biomarker-search paradigm through 
effective combination of computational and experimental techniques to enhance biomarker 
discovery from the rather low-yield trial-and-error methods in current use. Our paradigm 
involves analysis of gene expression data for identification of differentially expressed genes 
in cancer versus controls in conjunction with prediction of proteins that can be secreted into 
blood and then excreted into urine. The results obtained with primary tumor tissues from 
patients with gastric cancer, the number two cancer killer in the world, have demonstrated 
the success of this approach (Cui et al., 2008, 2011a; Hong et al., 2011). In addition, 
considerable effort has also been invested into the use of gene expression profiling 
techniques by others to elucidate their utility in predicting metastasis and survivability in 
ovarian cancer (Lancaster et al., 2006; Sabatier et al., 2009). 
Herein we focus our discussion on the in vitro use of an ovarian carcinoma cell line, SKOV-3 
cells (Warrenfeltz et al., 2008; Puett et al., 2010; Cui et al., 2011b,c), rather than tumor tissues, in 
part because of the desire to work with an established cell line in which continuing studies can 
be performed in a controlled and reproducible manner. Such cell lines have provided an 
enormous wealth of information on the characteristics of ovarian cells and their responses to 
various inhibitors or growth factors (Choi et al., 2007; Leung & Choi, 2007; Mandai et al., 2007). 
The question being addressed is whether transcriptomic profiling can be used to determine if 
LH, acting on LHR+ cells, is stimulatory, inhibitory, or has no effect on ovarian carcinoma 
cells. Hence, the experimental design has been focused on LH-mediated effects on cancer cells, 
not if LH is involved in the transformation process of an epithelial-to-carcinoma cell. Due to a 
considerable interest in the development of reliable serum or urine biomarkers for early 
detection of ovarian cancer, the results of earlier work are also mentioned. This chapter 
provides a summary of those studies and links them to other related findings. 
2. Properties of the SKOV-3 ovarian carcinoma cell line 
The SKOV-3 human ovarian cancer cell line was selected since it does not express LHR 
(Parrott et al., 2001; Mandai et al., 2007; Warrenfeltz et al., 2008) and can serve as a negative 
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control. Some lines do, however, appear to express LHR and respond to LH (Lau et al., 
2010). Following transfection with a full-length human LHR-pcDNA3 or an empty vector, 
two sub-lines were generated, one expressing about 12,000 receptors per cell (LHR+) and the 
other, i.e. the mock-transfected cells, that does not express LHR (LHR-) (Warrenfeltz et al., 
2008). 
The LHR+ cells bound radio-labeled human chorionic gonadotropin with a Kd of 0.3 nM in 
saturation binding assays and an IC50 of 0.8 nM in competition binding assays. The 
expressed LHR was functional as determined by increased production of cyclic AMP and 
inositol phosphates in response to LH. The LHR- cells, in contrast, exhibited no specific 
binding of human chorionic gonadotropin and showed no response to LH in terms of 
second messengers. 
Expression of LHR in the SKOV-3 cells, in the absence of LH, had no effect on cell migration 
or proliferation. It did, however, reduce the invasive index of the cells by a small margin. 
LH was found to reduce migration and proliferation of LHR+ cells but not of LHR- cells, 
while the invasiveness was not altered (Warrenfeltz et al., 2008).  
3. The transcriptomic profile of SKOV-3 Cells: Alterations associated with 
LHR expression and activation 
RNA was extracted from SKOV-3 cells (Warrenfeltz et al., 2008), and the resulting cDNAs 
were analyzed by Almac Diagnostics (Durham, NC, USA) using the Affymetrix Human 
U133 Plus2 Arrays (Cui et al., 2011c). In a parallel study on microRNA expression, the 
ovarian cancer DSATM array (Almac Diagnostics) was used (Cui et al., 2011b). The 
advantages in using ovarian cancer-specific arrays include the gathering of extensive 
amounts of novel mRNA data that are not covered by other platforms and putting both 
microRNA and mRNA probes on the same chips, hence avoiding potential noise introduced 
during data collection on separate chips. Gene expression profiling was done on both the 
LHR- and the LHR+ cells, and gene-expression data were also collected on the latter at 
multiple time points, specifically at 1, 4, 8, and 20 h after incubation with human LH. qRT-
PCR was carried out to validate a few significantly altered  gene expression patterns 
detected through microarray data analyses (Cui et al.,  2011c).  
4. Altered gene expression and pathways associated with LHR expression 
and activation 
Among the ~100,000 transcripts profiled in this study, 2,210 and 4,297 were found to show 
up-regulation and down-regulation with at least 2-fold changes between the LHR+ SKOV3 
cells and the control cells, respectively. Most of these differentially expressed transcripts are 
involved in cell division and in DNA replication and transcription, while genes primarily 
involved in carbohydrate transport/metabolism and lipid metabolism, cell communication, 
and ECM interaction were only down-regulated. 
When the cells were exposed to LH, 14,903 transcripts exhibited elevated expression, which 
extend the above functions to include posttranslational modification, RNA processing and 
modification, intracellular trafficking and secretion, signal transduction mechanisms, and 
coenzyme metabolism, while 10,389 transcripts found to be down-regulated were associated 
with cellular defense mechanisms based on our enrichment analyses against COG functions 
(Tatusov et al., 2000).  
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In total, 2,373 genes were differentially expressed in LHR+ cells (in the absence of LH) 
versus control (LHR- cells) or LH-treated LHR+ cells. Of these, 689 genes are cancer 
relevant and 265 are highly expressed in the ovary (GeneGo, 2000). These genes 
participate in pathways involved in the cell cycle, focal adhesion, cytokine-cytokine 
receptor interaction, regulation of the actin cytoskeleton, purine metabolism, and the key 
signaling pathways involved in cell growth, e.g. MAPK, TGF-ǃ, p53, and Jak-STAT. 
Functional analysis revealed that five major families, namely growth factors, translation 
regulators, transporters, GPCRs, and ligand-dependent nuclear receptors, were 
significantly enriched (Fig. 1).  
 
 
 
Fig. 1. Distribution of the 2,373 differentially expressed genes in SKOV-3 cells across 13 
major functional families. Each red bar represents the percentage of differentially expressed 
genes associated with LHR expression; each green bar represents the percentage of 
differentially expressed genes upon incubation with LH; each blue bar is the percentage of 
all human genes. The y-axis represents the percentage; the x-axis denotes functional 
families. 
Twelve gene clusters, each containing a highly co-expressed pattern, were identified among 
the 2,373 genes through a clustering analysis, termed a self-organizing map (SOM) 
(Kohonen 1982) (Table 1). On each gene cluster, Gene Ontology (GO) and pathway 
enrichment analyses were conducted to identify functional groups and cellular processes 
that are possibly affected by LHR expression and activation. The details of the findings are 
discussed elsewhere (Cui et al., 2011c), but the major observations are as follows: LHR 
expression in control SKOV-3 cells seems to have a positive impact on the activation of gap 
junctions and the associated growth signaling pathways, and to have moderately 
suppressed apoptosis, DNA mismatch repair, and the Ras-independent pathways in NK 
cell-mediated cytotoxicity, which are overall advantageous to cell growth; LH, 
subsequently, regulated expression of genes involved in the cell cycle, p53 and VEGF 
signaling, gap junction pathways, immune responses, and the complement and coagulation 
cascades, as well as a few metabolic pathways (Cui et al., 2011c).  
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Earlier in vitro studies demonstrated that LHR expression, in the absence of LH, slightly 
inhibited invasiveness, but had no effect on cell proliferation or migration. The addition of 
LH reduced the growth rate and migratory properties, but was without effect on 
invasiveness (Warrenfeltz et al., 2008). The current transcriptomic analysis shows that the 
observed expression changes in the above-mentioned pathways support the previous 
observations about the measured cellular properties (Warrenfeltz et al., 2008; Cui et al., 
2011c). 
 
 
LHR activated  genes 
 Clusters 
LHR-,LHR+,LH 
1-20h (# of genes)
Enriched GO functions/pathways (P-value) 
LH(↑) 
C1 
  
144  
extracellular matrix structural constituent    6.54E-04  
platelet-derived growth factor alpha-receptor activity 
4.38E-03 
regulation of vesicle fusion  4.38E-03 
hydroxyacid-oxoacid transhydrogenase activity 4.38E-03 
 
pathways: 
TCR 9.66E-0.2; EGFR1 1.68E-01; IL4 1.79E-01 
C2  
 
157 
negative regulation of apoptosis  3.57E-04 
leukocyte differentiation 5.75E-04 
carboxylic acid metabolic process 7.47E-04 
 
pathways: 
EGFR1 2.09E-03; TGFBR 4.94E-03;  
ID  9.55E-03; Kit Receptor 4.23E-02 
C3  
152 
multicellular organismal development  3.80E-06 
cell proliferation  2.31E-05 
cyclic-nucleotide phosphodiesterase activity  2.86E-04 
regulation of transcription, DNA-dependent  3.44E-04 
cell-cell signaling  4.49E-04 
 
pathways: 
Hematopoietic cell lineage  1.40E-02 
LH(-) 
C4 
 
205 
nervous system development  7.37E-05 
neurogenesis  7.84E-04 
notch binding  1.71E-03 
calcium ion binding  2.16E-03 
cell morphogenesis  4.22E-03 
 
pathways: 
NOTCH  8.29E-02 
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LHR activated  genes 
 
Clusters 
LHR-,LHR+,LH 
1-20h (# of genes)
Enriched GO functions/pathways (P-value) 
LH(↓) 
C5  
 
157 
response to external stimulus 1.08E-04 
positive regulation of cellular metabolic process  1.54E-05 
 
pathways: 
Androgen Receptor  8.42E-02; EGFR1  2.32E-01 
C6  
 
270 
cadmium ion binding  1.70E-06 
transcription  2.32E-04 
spermidine biosynthetic process  5.52E-04 
regulation of RNA metabolic process  7.51E-04 
 
pathways: 
MT-Heavy Metal-Pathway  1.96E-04; TCR  2.71E-02; IL4 
6.76E-02; TNF alpha/NF-kB  9.59E-02 
C7  
 
167 
neutrophil chemotaxis  5.52E-06 
positive regulation of heart rate  2.03E-05 
calcium-mediated signaling  6.13E-05 
leukocyte chemotaxis  9.57E-05 
regulation of cell migration  2.02E-04 
 
pathways: 
IL-7  9.19E-02; ID  1.60E-01 
LHR suppressed genes 
 Clusters Enriched GO functions/pathways (P-value) 
LH(↑) 
C8  
 
145 
extracellular region  6.34E-11 
collagen fibril organization  2.68E-05 
complement component C3b binding  3.63e-05 
fibrillar collagen  4.56E-05 
inflammatory response  9.80E-05 
response to external stimulus  3.44E-04 
protein digestion  3.98E-04 
 
pathways 
IL-7  2.84e-03; IL3  3.00E-01; Wnt  3.98e-01 
C9  
 
261 
alpha-amylase activity  4.37E-11 
amylase activity  2.61E-10 
calcium ion binding  5.02E-09 
homophilic cell adhesion  3.57E-07 
synaptogenesis  3.67E-06 
 
 
pathway: 
IL-7  1.16E-01; ID  2.00-01; EGFR1  3.90E-01 
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LHR suppressed genes 
 Clusters Enriched GO functions/pathways (P-value) 
LH(-) 
C10 
 
288 
proteinaceous extracellular matrix  6.00E-09 
polysaccharide binding  3.04e-08 
glycosaminoglycan binding  2.22E-06 
regulation of defense response  6.56E-06 
G-protein signaling, coupled to IP3 second messenger  1.15E-
05 
enzyme inhibitor activity  3.59E-05 
 
pathways: 
Wnt  5.23E-02; EGFR1  1.81E-01 
LH(↓) 
C11 
 
71 
regulation of aldosterone metabolic process  9.16E-06 
regulation of hormone metabolic process  5.93E-04 
auditory receptor cell differentiation  1.36E-03 
epidermis development  1.54E-03 
growth factor activity  2.44E-03 
 
pathways: 
NOTCH  1.58E-02; TGFBR  4.74E-02 
C12 
 
191 
cell cycle phase  1.56E-43 
mitosis  9.04E43 
microtubule cytoskeleton 4.80E-19 
 
pathways: 
BCR  5.92E-02 
Table 1. Enriched GO functions and pathways in each of the 12 gene clusters identified from 
the differentially expressed genes (modified and extended from Cui et al., 2011c). Plots 
represent the expression pattern across six groups (LHR- SKOV3 control, LHR expression 
but with no added LH, and incubation of the LHR+ cells with LH for 1, 4, 8, and 20 h.)  “↑” 
and “↓“ denote responses of up-regulation and down-regulation of gene expression, 
respectively and “-“ denotes no alteration of gene expression. 
Some of the affected major processes related to cell growth and death (Cui et al., 2011c) have 
been further investigated. It was found that LHR expression in the control cells led to the 
up-regulation of genes involved in gap junction, purine metabolism, calcium signaling, and 
actin cytoskeleton regulation, indicating a possible activation of these processes at a 
moderate level. In particular, the up-regulation of genes involved in gap junction formation 
and function may indicate reduced tumor progression and metastasis (Holder et al., 1993).  
LH-activated genes are involved in VEGF signaling, the Toll-like receptor signaling, and the 
B-cell receptor signaling pathway, as well as those involved in gap junction and Notch 
signaling, which may accelerate cell-cell communication and influence several key aspects of 
normal cell development by regulating differentiation, proliferation, and apoptosis (Sjolund 
et al., 2005). One particularly interesting observation was that the substantially increased 
expression of the tumor necrosis factor member 10 gene (TNFSF10), involved in natural 
killer cell-mediated cytotoxicity, may induce apoptosis (Pan et al., 1997). LH also led to 
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considerable activation of the genes for interleukin-6 (IL-6) and IL-8, pleiotropic cytokines, 
which are believed to be involved in ovarian carcinogenesis and angiogenesis (Asschert et 
al., 1999; Schwartz et al., 2001; Chou et al., 2005). 
5. Comparative profiling between SKOV-3 cells and normal Human Ovarian 
Surface Epithelium (HOSE) cells, and molecular markers 
The genes most highly expressed (top 5%) in SKOV-3 cells are largely different from those in 
the normal HOSE cells. It was found that 1,056 such genes were specific to the LHR- SKOV-
3 cells, involved in regulation of translation, cell division, chromosome partitioning, post-
translational modifications, protein turnover, chaperones, and signal transduction 
mechanisms, suggesting increased cell growth and proliferation. Another 689 genes were 
specific to the LH-treated cells and found to be associated with coenzyme metabolism, post-
translational modifications, nucleotide transport, DNA replication and repair, intracellular 
trafficking, and secretion. 
Two lists of genes, one with 185 up-regulated genes and the other with 248 down-
regulated genes, were identified to show differential expressions between normal and 
cancer cells regardless of LHR expression or activation (Cui et al., 2011c). Functional 
analyses revealed that the up-regulated genes are involved in cell-cell communication, 
ECM-receptor interaction, focal adhesion, cell division and chromosome partitioning, as 
well as carbohydrate transport and metabolism, which are essential to cancer growth. Of 
interest, 106 of these genes were found to be specific to ovarian cancer, based on our 
analyses of their differential expression patterns in ovarian cancer versus those of other 
human diseases with available genome-scale expression data in the public database 
(http://bioinfosrv1.bmb.uga.edu/DMarker/). 
These results engender confidence in proposing some of them as potential molecular 
markers for ovarian epithelial carcinoma cells versus normal HOSE cells. Using a prediction 
method that we recently developed and validated (Cui et al., 2008), 103 of these genes were 
predicted to have their protein products secreted into circulation, thus providing another 
important pool of potential serum markers for ovarian cancer (Cui et al., 2011c).  
6. Known therapeutic targets involved in the cellular response to LH action 
As of now, 39 genes have been proposed as therapeutic targets for ovarian cancer based 
on our database search against the Therapeutic Target Database (TTD) (Mandai et al., 
2007). Among them, endothelin-1 (ET-1), stromal cell-derived factor 1 (SCD-1), and  
insulin-like growth factor II (IGF2) show the most significant expression changes 
associated with LH. 
ET-1, acting through its receptor, ETAR, has been extensively studied in its physiological 
roles in vasoconstriction and proliferation of smooth muscle cells, as well as its 
pathophysiological role in hypertension, heart failure, and coronary vasospasms. Recently it 
was also identified as important in ovarian cancer initiation and progression (Bagnato & 
Rosano, 2008; Bhalla et al., 2009; Rosano et al., 2010). These findings have led to the 
development of endothelin-converting enzyme-1 inhibitors and small interfering RNAs as 
new therapeutic agents for ovarian cancer (Rayhman et al., 2008). LH increases gene 
expression of ET-1 by some 10-fold, peaking at 1 h, an observation documented by qRT-PCR 
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(Cui et al., 2011c). This observation, along with findings that  ETAR shows a moderate 
elevation in expression, while endothelin-converting enzyme-1 and the endothelin B 
receptor show no changes in their expression, may indicate a possible enhancement of cell 
proliferation in response to LH.  
SCD-1 has been reported to increase the invasiveness and migration of breast cancer cells 
(Kang et al., 2005), and IGF2 is known to be a fetal promoter of cell proliferation in various 
cancers (Zaina et al., 2002). The up-regulation of these genes may suggest that LH exerts 
positive effects on tumor growth and metastasis. However, reduced cell growth is 
manifested in LH-treated cells (Warrenfeltz et al., 2008), and thus expression of the negative 
regulators, e.g. c-JUN, TNFSF10, and MMPs (Cui et al., 2011c), must assume a dominant role 
in relating gene expression and tumor cell properties. 
7. MicroRNA regulation involved in LH treatment of LHR+ SKOV3 cells 
In addition to the aforementioned ~100,000 protein-encoding transcripts, 132 microRNAs 
were selectively profiled on the DSA array. It is known that small non-coding RNAs serve in 
various regulatory roles in degradation of mRNAs and inhibition of translation (Bartel, 
2004) in all major cellular processes, such as differentiation, apoptosis, and proliferation 
(Ambros, 2004; Bartel, 2004). Many microRNAs are androgen related, and their deregulation 
is highly correlated with initiation, progression, and prognosis of cancer (Calin et al., 2005; 
Yanaihara et al., 2006; Bloomston et al., 2007; Ambs et al., 2008; Garzon et al., 2008; Schetter 
et al., 2008; Croce, 2009; Wyman et al., 2009).  
Recently, 17 microRNAs were found to be differentially expressed in LHR+ SKOV-3 cells 
versus control cells (Cui et al., 2011b), specifically: six up-regulated (miR-101-1, -101-2, -199b, 
-559, -573, and -7-3) and 11 down-regulated (miR-103-2, -200c, 151, 29c, 301b, 548a2, 552, 561, 
566, 613, and 642). After incubation with LH, 57 microRNAs were found to be differentially 
expressed, including the most highly-expressed microRNAs, such as miR-21, -200c, -593, -
103-1, and -124-3. Some of these microRNAs are located in the fragile sites (also called hot 
spots) in the human genome (Calin et al., 2004; Bignell et al., 2010), where genomic 
alternations in these regions were found to be associated with certain types of cancer. For 
example, the loss of 11p15 (covering miR-210) is found in ovarian cancer (Peng et al., 2000), 
and amplification of 17q23 (covering miR-301a and miR-21) is found in breast cancer 
(Barlund et al., 2000), as well as those reported (Calin et al., 2002; He et al., 2005).  
The present focus is to examine LH-mediated transcriptional changes of the microRNAs, but 
it should be mentioned that the SKOV-3 cancer cells have probably undergone some 
genomic alternations, resulting in altered gene expression levels in the control cancer cells 
that cannot be determined by our current expression data. Collectively, 65 microRNAs have 
been identified to be differentially expressed in LHR+ SKOV-3 cells versus control. The 
mRNAs with which the microRNA may interact have been studied in order to infer 
potentially regulated processes involving the microRNAs (Cui et al., 2011b).  
Specifically, Spearman correlation analysis was performed between the expression of the 65 
differentially-expressed microRNAs and the expression of 60,860 well-annotated mRNAs 
across all sample groups under consideration, resulting in 62,150 and 931,009 microRNA-
mRNA pairs with significantly correlated expressions, positive or negative, using cutoffs 
|rho|>0.8 and P-value <0.05, where rho represents the Spearman correlation coefficient. 
More positively correlated microRNA-mRNA pairs than negatively correlated pairs were 
found for the vast majority of the microRNAs, except for nine microRNAs: miR-181B2, miR-
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582, miR-497, miR-559, miR-561, miR-101-1, miR-187, miR-572, and miR-301A. The 
prevalence in positively correlated microRNA-mRNA pairs suggests that such microRNAs 
are probably located in introns or 5’ untranslated regions of the corresponding mRNAs and 
hence are regulated by the same transcription regulators of their host genes. The negatively 
correlated pairs may indicate possible biochemically important interactions.  
MiRanda (Miranda et al., 2006) and TargetScan (Lewis et al., 2005) were applied for 
microRNA target prediction. A total of 584 genes were predicted to interact with the 65 
differentially expressed microRNAs. Although not all predicted pairs possess high 
correlations, it does show a trend that the percentage of predicted pairs decreased as the 
coefficients increase along its distribution. With the above cutoffs, only 155 genes were 
retained as highly-confident microRNA targets for further analysis. For each of the 65 
microRNAs under consideration, its function was predicted through identification of the 
functions and pathways enriched by their target genes; the functions of 16 differentially-
expressed microRNAs were so predicted (Cui et al., 2011b).  
For example, miR-199b-5p is predicted to participate in angiogenesis, nucleotide excision 
repair, the PDGF signaling pathway, the cadherin/Wnt/integrin signaling pathway, 
apoptosis, and the MAPK signaling pathway. MiR-101 is predicted to be involved in the 
Wnt/MAPK/cadherin signaling pathway, as well as in hypertrophic cardiomyopathy, 
melanogenesis, the metabotropic glutamate receptor group III pathway, and ubiquitin-
mediated proteolysis. In addition, it may also be involved in the regulation of the mRNAs 
involved in cyclic AMP regulation; cyclic AMP-specific phosphodiesterase 4D (PDE4D) was 
highly up-regulated by LH in LHR+ cells (Cui et al., 2011c). MiR-29c is predicted to regulate 
ECM-receptor interaction, focal adhesion, collagen ǂ chains, and the integrin signaling 
pathway. It is noteworthy that several of the microRNAs are predicted to be potentially 
involved in regulation of various tyrosine and serine/threonine kinases (Cui et al., 2011b). 
The main regulation of miR-129 is that of angiogenesis, the Wnt signaling pathway, 
transcription regulation, and cell junction. The predicted involvement of miR-199b-5p, miR-
101, and miR-129 in the Wnt pathway may suggest its possible role in ovarian tumorigenesis 
(Gatcliffe et al., 2008).  
To affirm that some microRNAs participate in the LH regulation of cancer cells, the 
experimentally validated targets of the 65 differentially-expressed microRNAs were 
examined, and 70 such genes were extracted from miRecords (Xiao et al., 2009). Of these, 20 
genes are differentially expressed in the LH-treated cells, and some are known to be 
involved in the regulation of cell migration and proliferation (IRS1, IRS2, IL6R, TPM1, GLI1, 
BMPR2, GRN), cell surface receptor-linked signal transduction (SOCS5, RAF1), anti-
apoptosis (FAS, MCL1, SGK3), and transcription regulation (DNMT3B, GLI1, EZH2) (Cui et 
al., 2011b). Only six of the 20 genes exhibited highly correlated expression patterns with 
some of the 65 microRNAs (Cui et al., 2011c), namely IRS1, IRS2, and RAF1 with miR-7-1, 
SGK3 and MTAP with miR-21, and GRN with miR-659. The expression changes of these 
genes indicate that LH may impose a positive regulation of cell proliferation, nucleotide 
metabolic processes, and cell surface receptor-linked signal transduction, and a negative 
regulation of apoptosis on ovarian cancer cells through these microRNAs.   
Additionally, 54 oncogene and tumor-suppressor genes (Jiang et al., 2009; Bignell et al., 
2010) were examined to determine if some of the microRNAs may participate in 
transcriptional regulation (Cui et al., 2011b). It was found that miR-21 was up-regulated 
while its target, TPM1, a tumor suppressor gene, was down-regulated in response to LH, 
suggesting a role of miR-21 in inhibiting apoptosis and subsequently having a positive 
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impact of LH on cancer development. However, our other observations such as up-
regulation of NF1, RB1, and SUFU may indicate a negative effect on cancer growth, 
consistent with our previous report (Warrenfeltz et al., 2008).  
As important gene regulators, microRNAs exhibit characteristics that allow speculation on 
some of the key roles they may have in regulating the downstream LHR signaling in ovarian 
cancer. The indicative clues of regulating apoptosis and cell proliferation may provide 
useful guidance for further research on the causes and treatment of ovarian cancer. It should 
be noted from the above analysis that detection of microRNA-mRNA pairs is a key step to 
understand the functions of microRNAs. All current computational programs used for 
predicting microRNA/mRNA interactions are mainly based on information embodied in 
the sequence and structure (Dai & Zhou, 2010). Yet the Argonaute (Ago) proteins have a 
central role in recognizing and binding to target mRNAs (Wang et al., 2010), and we thus 
anticipate that a method taking into consideration the sequence or structure information of 
AGO proteins may efficiently improve the prediction performance.  
8. Conclusions 
Numerous studies have appeared on the physiological roles and biochemical mechanisms of 
the pituitary gonadotropins, LH and FSH, in developmental and reproductive processes, as 
well as the pathophysiology associated with aberrant expression and mutations in the genes 
encoding the three gonadotropin subunits and the two gonadotropin receptors. Recent 
experimental findings and epidemiological evidence has arisen suggesting that the 
hormones and receptors are also involved in the development and/or progression of 
ovarian cancer. There is, however, much controversy associated with the role(s), if any, of 
the gonadotropins in ovarian cancer. Research undertaken in our laboratory has focused on 
experimental measurements of altered cellular properties and transcriptomic profiling of 
SKOV-3 cells in response to LH, in an effort to clarify aspects of this important area 
(Warrenfeltz et al., 2008; Puett et al., 2010; Cui et al., 2011a,b,c). This work has established 
that the expression of many genes and microRNAs is altered by LHR expression in SKOV-3 
cells and by activation of the receptor with its natural ligand, LH. Some of the changes 
involve genes and pathways associated with cell growth, apoptosis, and many more cellular 
processes. Of interest was the observation that many genes had altered expression patterns 
upon expression of LHR in the absence of ligand. Such changes presumably arise from 
ligand-independent actions of LHR and from the unoccupied receptor adopting an active, or 
active-like, conformation periodically. Incubation of the cells with LH resulted in the 
expression of myriad genes (over 2,000), many of which are important in biological 
processes such as proliferation, apoptosis, and others. Further studies on microRNAs 
identified 65 that exhibited altered expression in LHR+ cells and LHR+ cells incubated with 
LH. Some of these microRNAs may aid in diminishing cell proliferation and possibly 
enhancing apoptosis. The conflicting results often obtained with transcriptomic profiling, 
including evidence for both positive and negative enhancement of important processes such 
as proliferation, apoptosis, etc., documents the need to always have experimental studies on 
the cellular phenotype with regard, in the present case, to LHR expression and LH-
mediated LHR activation. The net effect, as determined from cell studies is a slight 
inhibition of proliferation, invasiveness, and migration upon LHR expression and 
activation. Of potential importance was the observation that some 100 genes were 
identified that may lead to secreted proteins, thus offering an array of possible serum 
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biomarkers specific for ovarian cancers expressing LHR in the presence of circulating LH, 
often the case in post-menopausal women. 
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